The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: A sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide
Antineoplastic Combined Chemotherapy Protocols
The NHL-15 program can be administered safely and effectively to achieve high rates of durable remission when used for the treatment of advanced stage, aggressive, non-Hodgkin's lymphomas. The 5%-15% improvement in 5-year OS compared with historical CHOP, according to the IPI/aaIPI model (in LI and HI risk groups), is encouraging. Further evaluation and prospective testing of the NHL-15 protocol appears to be warranted.